BioSpace News Archive

Calliditas Therapeutics AB announced the submission of a New Drug Application to the U.S. Food and Drug Administration for Nefecon, a novel oral formulation targeting down regulation of IgA1 for the treatment of primary IgA Nephropathy.

Masimo announced the findings of an observational, retrospective study published in Pediatrics International.

Increasing cases of cancer among infants to bolster the sales for pediatric neuroblastoma treatment market

The demand in the global cardiac rehabilitation market is estimated to increment at a significant CAGR of 5.4% during the forecast period of 2016 to 2024, gaining traction from a number a factors, such as rise in geriatric population, growing burden of cardiovascular diseases, and increase in global initiatives regarding the awareness for cardiovascular diseases.

Business Intelligence platforms enable healthcare organizations to build applications that help them understand their processes and use technology to help ensure healthcare quality and control cost.

The global needle free drug delivery device market is likely to witness significant growth during the course of forecast period from 2018 to 2026.

The rise in target patient population is considered a key factor boosting the global gene expression market and likely to continue doing so in the forecast period set between 2020 and 2030.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company will host a virtual investor event to discuss Merck’s broad HIV program and the newly announced collaboration with Gilead Sciences. Investors, analysts, members of the media and the general public are invited to listen to a live audio

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that the University of Notre Dame has been granted a Vietnamese patent on spider silk technology developed pursuant to the collaborative research agreement with Kraig .

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will host a virtual R&D day on Monday, March 22, 2021 from 9:00 am to 11:00 am ET. The program will cover BioCryst’s unique, proven and prolific approach to developing oral medicines for rare diseases, with a focus on BCX9930, an oral Factor D inhibitor being developed as a monotherapy for the treatment of complement-mediated diseases.